Alnylam Pharmaceuticals SG&A Expenses 2010-2024 | ALNY

Alnylam Pharmaceuticals sg&a expenses for the twelve months ending June 30, 2024 were $0.856B, a 1.41% increase year-over-year.

  • Alnylam Pharmaceuticals annual sg&a expenses for 2023 were $0.796B, a 3.24% increase from 2022.
  • Alnylam Pharmaceuticals annual sg&a expenses for 2022 were $0.771B, a 24.17% increase from 2021.
  • Alnylam Pharmaceuticals annual sg&a expenses for 2021 were $0.621B, a 5.48% increase from 2020.

Alnylam Pharmaceuticals SG&A Expenses 2010-2024 | ALNY

  • Alnylam Pharmaceuticals annual sg&a expenses for 2023 were $0.796B, a 3.24% increase from 2022.
  • Alnylam Pharmaceuticals annual sg&a expenses for 2022 were $0.771B, a 24.17% increase from 2021.
  • Alnylam Pharmaceuticals annual sg&a expenses for 2021 were $0.621B, a 5.48% increase from 2020.